MedTrace Logo

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

NCT05222932 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-08-07

No results posted yet for this study

Summary

This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.

Conditions

Interventions

BIOLOGICAL

TILT-123

TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

DRUG

Avelumab

Anti-PDL1 antibody

Sponsors & Collaborators

  • TILT Biotherapeutics Ltd.

    lead INDUSTRY

Principal Investigators

  • Tuomo Alanko · Docrates Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-08
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States
  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05222932 on ClinicalTrials.gov